Institutional review board

AIM ImmunoTech Announces Commencement of Phase 2 Study of Ampligen® for the Treatment of Pancreatic Cancer

Retrieved on: 
Thursday, August 18, 2022 - 2:05pm

OCALA, Fla., Aug. 18, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases — including COVID-19, the disease caused by the SARS-CoV-2 virus — today announced the commencement of its Phase 2 study of Ampligen as a therapy for locally advanced pancreatic cancer (“LAPC”) (AMP-270) following receipt of Institutional Review Board (“IRB”) approval for the trial protocol.

Key Points: 
  • AIM Chief Executive Officer Thomas K. Equels commented, We are pleased to reach this important step in the development of Ampligen.
  • Receiving IRB approval for our Phase 2 study of Ampligen for the treatment of LAPC is the pivotal precursor to the recruitment, enrollment and treatment of patients with locally advanced pancreatic cancer.
  • The Companys Phase 2 study Investigational New Drug (IND) application was previously cleared by the U.S. Food and Drug Administration (FDA).
  • The AMP-270 clinical trial is a randomized, open-label, controlled, parallel-arm study with the primary objective of comparing the efficacy of Ampligen versus a no treatment control group following FOLFIRINOX for subjects with locally advanced pancreatic adenocarcinoma.

Four National Native Scholarship Providers Release National Study on College Affordability for Indigenous Students

Retrieved on: 
Wednesday, August 17, 2022 - 11:27pm

Denver, Colo., Aug. 17, 2022 (GLOBE NEWSWIRE) -- The National Native Scholarships Providers (NNSP) has released its first-ever National Study on College Affordability for Indigenous Students.

Key Points: 
  • Denver, Colo., Aug. 17, 2022 (GLOBE NEWSWIRE) -- The National Native Scholarships Providers (NNSP) has released its first-ever National Study on College Affordability for Indigenous Students.
  • Yet until NNSPs research, the national data on the effect of college affordability on Indigenous students college completion had not been fully explored.
  • Monette, CEO of the Cobell Scholarship Program administered by Indigenous Education, Inc., said, Data on college affordability for Native students now has new national visibility due to our scholarship organizations powerful data and research collaboration.
  • Collaborating with other nonprofits to form National Native Scholarship Providers is an important step in this process to explore college affordability, access to higher education, and the challenges Native students face, on and off campus.

Four National Native Scholarship Providers Release National Study on College Affordability for Indigenous Students

Retrieved on: 
Wednesday, August 17, 2022 - 11:30pm

DENVER, Aug. 17, 2022 /PRNewswire/ -- The National Native Scholarships Providers (NNSP) has released its first-ever National Study on College Affordability for Indigenous Students. The research and report, which were funded by a grant from Lumina Foundation, are the result of a collaboration of collection, data-sharing, analysis, and reporting between the nation's four Native scholarship providers: the American Indian College Fund, the Cobell Scholarship, the American Indian Science and Engineering Society, and Native Forward Scholars Fund (formerly American Indian Graduate Center). Researchers have found the primary obstacle to college completion is affordability, causing overall college student attrition. Yet until NNSP's research, the national data on the effect of college affordability on Indigenous students' college completion had not been fully explored.

Key Points: 
  • DENVER, Aug. 17, 2022 /PRNewswire/ --The National Native Scholarships Providers (NNSP) has released its first-ever National Study on College Affordability for Indigenous Students.
  • Yet until NNSP's research, the national data on the effect of college affordability on Indigenous students' college completion had not been fully explored.
  • Four National Native Scholarship Providers Release National Study on College Affordability for Indigenous Students.
  • PhotoThe first-ever National Study on College Affordability for Indigenous Students released by the National Native Scholarships Providers (NNSP).

Bluejay Therapeutics raises $41 million in Series B round to drive clinical trials in chronic hepatitis

Retrieved on: 
Tuesday, August 16, 2022 - 3:54pm

SAN MATEO, Calif., Aug. 16, 2022 (GLOBE NEWSWIRE) -- Bluejay Therapeutics announced today that it has closed a $41 million Series B round of finance led by Arkin Bio Ventures.

Key Points: 
  • SAN MATEO, Calif., Aug. 16, 2022 (GLOBE NEWSWIRE) -- Bluejay Therapeutics announced today that it has closed a $41 million Series B round of finance led by Arkin Bio Ventures.
  • It will also fund development of BJT-574, an orally bioavailable small molecule HBsAg inhibitor, into first-in-human clinical trials.
  • The companys first target indication is chronic Hepatitis B, which remains a worldwide prevalent disease with urgent unmet medical need.
  • The company believes that by reducing hepatitis B surface antigen and restoring adaptive immunity a functional cure could be achieved for patients.

Viracta Therapeutics Appoints Jane Chung, R.Ph., to its Board of Directors

Retrieved on: 
Thursday, August 11, 2022 - 2:00pm

SAN DIEGO, Aug. 11, 2022 /PRNewswire/ -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced the appointment of Jane Chung, R.Ph., as an independent member to its Board of Directors.

Key Points: 
  • SAN DIEGO, Aug. 11, 2022 /PRNewswire/ -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced the appointment of Jane Chung, R.Ph., as an independent member to its Board of Directors.
  • "Ms. Chung's unique combination of commercial and executive experience in oncology make her an ideal fit for Viracta's Board," said Roger J. Pomerantz, M.D., F.A.C.P., Chairman of the Board of Directors of Viracta.
  • It is my pleasure to welcome her to the Board and I am eager to begin working together."
  • Viracta assumes no obligation and does not intend to update these forward-looking statements, except as required by law or applicable regulation.

Bragar Eagel & Squire, P.C. Is Investigating TuSimple, Atara, Mercury, and the WWE and Encourages Investors to Contact the Firm

Retrieved on: 
Saturday, August 6, 2022 - 2:00am

Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.

Key Points: 
  • Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.
  • The article alleges that one of the Companys autonomously driven trucks left its lane of travel without warning before striking a cement barricade.
  • The article also reveals that the Federal Motor Carrier Safety Administration has launched a safety compliance investigation.
  • For more information on the WWE investigation go to: https://bespc.com/cases/WWE
    About Bragar Eagel & Squire, P.C.

ELYSIAN, Jan Zakin Team Up to Launch Inaugural NFT Collection Aimed at Women Over 40

Retrieved on: 
Tuesday, August 2, 2022 - 3:00pm

The collection, featuring 41 unique NFTs in all, is inspired by Jan Zakin, an OB-GYN and co-owner of the Zakin winery.

Key Points: 
  • The collection, featuring 41 unique NFTs in all, is inspired by Jan Zakin, an OB-GYN and co-owner of the Zakin winery.
  • Zakin is an ELYSIAN Inspiring Woman and is on the cover of the magazine's Fall 2022 Travel & Technology issue.
  • Each NFT in this inaugural collection is embellished with a chic circuit board design, bridging the gap between the print and digital worlds.
  • An ELYSIAN NFT doubles as an all-access pass, and some include a gift of Zakin wine, tickets to upcoming events and other perks.

Guided Therapeutics Receives Institutional Review Board Approval to Start Clinical Study for FDA Approval of the LuViva® Advanced Cervical Scan

Retrieved on: 
Wednesday, July 20, 2022 - 2:00pm

Guided Therapeutics, Inc. (OTCQB: GTHP), the maker of a rapid and painless testing platform for cervical cancer detection based on its patented biophotonic technology, announced that it has obtained Institutional Review Board (IRB) approval to initiate its clinical trial aimed at obtaining FDA approval for the Companys flagship product, the LuViva Advanced Cervical Scan.

Key Points: 
  • Guided Therapeutics, Inc. (OTCQB: GTHP), the maker of a rapid and painless testing platform for cervical cancer detection based on its patented biophotonic technology, announced that it has obtained Institutional Review Board (IRB) approval to initiate its clinical trial aimed at obtaining FDA approval for the Companys flagship product, the LuViva Advanced Cervical Scan.
  • The study is expected to start enrolling patients in about 30 to 60 days.
  • The Companys first product is the LuViva Advanced Cervical Scan, a non-invasive device used to detect cervical disease instantly and at the point of care.
  • The Guided Therapeutics LuViva Advanced Cervical Scan is an investigational device and is limited by federal law to investigational use in the U.S. LuViva, the wave logo and "Early detection, better outcomes" are registered trademarks owned by Guided Therapeutics, Inc.

Bragar Eagel & Squire, P.C. Is Investigating TG Therapeutics, Allianz, GoodRx, and the WWE and Encourages Investors to Contact the Firm

Retrieved on: 
Saturday, July 16, 2022 - 2:00am

Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.

Key Points: 
  • Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.
  • On this news, TG Therapeutics' stock price fell $8.16 per share, or 34.93%, to close at $15.20 per share on November 30, 2021.
  • On this news, GoodRxs stock fell $2.78, or 25.9%, to close at $7.97 on May 10, 2022, thereby injuring investors.
  • For more information on the WWE investigation go to: https://bespc.com/cases/WWE
    About Bragar Eagel & Squire, P.C.

Emerald Health Pharmaceuticals Announces Resignation of CEO and CFO

Retrieved on: 
Monday, July 11, 2022 - 5:41am

We thank Jim as a co-founder and chief executive as well as Lisa for their leadership, focused commitment, and execution in building Emerald Health Pharmaceuticals into a clinical-stage biotechnology company, said Jim Heppell, Chair of the Board.

Key Points: 
  • We thank Jim as a co-founder and chief executive as well as Lisa for their leadership, focused commitment, and execution in building Emerald Health Pharmaceuticals into a clinical-stage biotechnology company, said Jim Heppell, Chair of the Board.
  • Emerald Health Pharmaceuticals Inc. (Company), Jim DeMesa, and Lisa Sanford recently each received a Wells Notice from the staff (Staff) of the Securities and Exchange Commission (Commission).
  • About Emerald Health Pharmaceuticals Inc.
    Emerald Health Pharmaceuticals is developing novel product candidates for the treatment of CNS, autoimmune, and other diseases.
  • Emerald Health Pharmaceuticals' investigational drug products have not been approved or cleared by the FDA.